Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Osteoporosis, Postmenopausal/drug therapy"'
Autor:
Nerea Alonso, Omar M E Albagha, Asim Azfer, Beatriz Larraz-Prieto, Kathryn Berg, Philip L Riches, Barbara Ostanek, Tomaz Kocjan, Janja Marc, Bente L Langdahl, Stuart H Ralston
Publikováno v:
Alonso, N, Albagha, O M E, Azfer, A, Larraz-Prieto, B, Berg, K, Riches, P L, Ostanek, B, Kocjan, T, Marc, J, Langdahl, B L & Ralston, S H 2023, ' Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy ', Annals of the Rheumatic Diseases, vol. 82, no. 7, pp. 985-991 . https://doi.org/10.1136/ard-2022-223618
ObjectivesTeriparatide (TPTD) is an effective treatment for osteoporosis but the individual response to therapy is variable for reasons that are unclear. This study aimed to determine whether the response to TPTD might be influenced by genetic factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df1049742e9ffdbf5491e6317da0fc9d
https://pure.au.dk/portal/da/publications/genomewide-association-study-identifies-genetic-variants-which-predict-the-response-of-bone-mineral-density-to-teriparatide-therapy(34e42bcd-5709-40ce-8190-7b1b6ac2ad79).html
https://pure.au.dk/portal/da/publications/genomewide-association-study-identifies-genetic-variants-which-predict-the-response-of-bone-mineral-density-to-teriparatide-therapy(34e42bcd-5709-40ce-8190-7b1b6ac2ad79).html
Autor:
Alma B. Pedersen, Nickolaj Risbo, George Kafatos, David Neasham, James O’Kelly, Vera Ehrenstein
Publikováno v:
Pedersen, A B, Risbo, N, Kafatos, G, Neasham, D, O'Kelly, J & Ehrenstein, V 2023, ' Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark : a population-based cohort study ', Archives of Osteoporosis, vol. 18, no. 1, pp. 19 . https://doi.org/10.1007/s11657-023-01210-4
Summary Persistence with initial treatment was highest after 1 year, decreasing afterwards. Persistence was highest for denosumab followed by alendronate. We identified several factors associated with treatment persistence, some of which were the sam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4e867295b08b684e6582a6421eda67b
https://pure.au.dk/portal/da/publications/utilization-patterns-and-factors-associated-with-persistence-of-new-users-of-antiosteoporosis-treatment-in-denmark(f800edad-08da-44aa-ab97-bb7fae8e5ec4).html
https://pure.au.dk/portal/da/publications/utilization-patterns-and-factors-associated-with-persistence-of-new-users-of-antiosteoporosis-treatment-in-denmark(f800edad-08da-44aa-ab97-bb7fae8e5ec4).html
Publikováno v:
Sølling, A S, Harsløf, T, Bruun, N H & Langdahl, B 2021, ' The predictive value of bone turnover markers during discontinuation of alendronate : the PROSA study ', Osteoporosis International, vol. 32, no. 8, pp. 1557-1566 . https://doi.org/10.1007/s00198-021-05835-4
In patients discontinuing ALN after a median of 7.0 years (range 5.0-20.0 years), BMD decreased, and bone turnover markers increased within the premenopausal reference range over 2 years. Increased p-CTX after 3 months was associated with greater bon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bd9aa6cdf632a5cc20f9727abccf333
https://vbn.aau.dk/da/publications/d18ccd45-b6ab-4b67-bd1a-771c4aafa18e
https://vbn.aau.dk/da/publications/d18ccd45-b6ab-4b67-bd1a-771c4aafa18e
Autor:
Arnaud Constantin, Adeline Ruyssen-Witrand, Laurence Ferrieres, Yannick Degboé, Michel Laroche
Publikováno v:
Archives of Osteoporosis
Archives of Osteoporosis, Springer Verlag, 2020, 15 (1), ⟨10.1007/s11657-019-0672-4⟩
Archives of Osteoporosis, Springer Verlag, 2020, 15 (1), ⟨10.1007/s11657-019-0672-4⟩
The mutual effects of drugs used in osteoporosis and cardiovascular diseases are a point of interest. A literature review and meta-analysis were conducted to address the impact of PTH analogs and anti-Rank ligand on cardiovascular events and overall
Autor:
Francisco de Assis Acurcio, Gustavo Machado, Cristina Mariano Ruas Brandão, Augusto Afonso Guerra Junior, Mariangela Leal Cherchiglia, Felipe Ferré, Eli Iola Gurgel Andrade
Publikováno v:
Revista de Saúde Pública, Vol 47, Iss 2, Pp 390-402 (2013)
Revista de Saúde Pública v.47 n.2 2013
Revista de Saúde Pública
Universidade de São Paulo (USP)
instacron:USP
Revista de Saúde Pública, Volume: 47, Issue: 2, Pages: 390-402, Published: JUN 2013
Revista de Saúde Pública v.47 n.2 2013
Revista de Saúde Pública
Universidade de São Paulo (USP)
instacron:USP
Revista de Saúde Pública, Volume: 47, Issue: 2, Pages: 390-402, Published: JUN 2013
OBJETIVO: Analisar os gastos com medicamentos para o tratamento da osteoporose na pós-menopausa e os fatores associados ao gasto médio per capita . MÉTODOS: Pareamento probabilístico-determinístico a partir das bases das Autorizações de Proced
Autor:
P. Haentjens, Filip Callewaert, Dirk Vanderschueren, Koen Milisen, Richard Kay, Cyrus Cooper, Serge Ferrari, Steven Boonen
Publikováno v:
International Journal of Clinical Practice, Vol. 63, No 12 (2009) pp. 1792-1804
AIMS: The efficacy of treatments for osteoporosis can be evaluated using a variety of study designs. This article aims to comprehensively review the evidence for bisphosphonate anti-fracture efficacy in postmenopausal women, discussing the strengths
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6ff977bc888985297c5f41e59a7de65
https://ora.ox.ac.uk/objects/uuid:69e19e47-6774-4543-84df-b3fa48dbed22
https://ora.ox.ac.uk/objects/uuid:69e19e47-6774-4543-84df-b3fa48dbed22
Publikováno v:
Archives of Osteoporosis
Summary We investigated reasons for non-treatment of osteoporosis and discontinuation of osteoporosis therapy. Barriers to treatment include patients’ preference for alternative treatments and a fear of possible side effects. Side effects are a com
Autor:
Steven Boonen, Jean-Jacques Body, Jean-Marc Kaufman, Yves Boutsen, Jean-Pierre Devogelaer, Jean-Yves Reginster, Pierre Bergmann, Stefan Goemaere, Serge Rozenberg
Publikováno v:
Osteoporosis international, 21 (10
Osteoporosis International : with other metabolic bone diseases, Vol. 21, no. 10, p. 1657-80 (2010)
Osteoporosis International
Osteoporosis International : with other metabolic bone diseases, Vol. 21, no. 10, p. 1657-80 (2010)
Osteoporosis International
Several drugs are available for the management of postmenopausal osteoporosis. This may, in daily practice, confuse the clinician. This manuscript offers an evidence-based update of previous treatment guidelines, with a critical assessment of the cur
Autor:
Jean-Jacques Body, Jean-Marc Kaufman, Jean-Pierre Devogelaer, Steven Boonen, Jean-Yves Reginster, Yves Boutsen, Stefan Goemaere, Pierre Bergmann, Valérie Gangji
Publikováno v:
International Journal of Clinical Practice
International journal of clinical practice, 63 (1
International Journal of Clinical Practice, Vol. 63, no. 1, p. 19-26 (2009)
International journal of clinical practice, 63 (1
International Journal of Clinical Practice, Vol. 63, no. 1, p. 19-26 (2009)
OBJECTIVES: To review the clinical value of bone turnover markers (BTM), to initiate and/or monitor anti-resorptive treatment for osteoporosis compared with bone mineral density (BMD) and to evaluate suitable BTM and changes in BTM levels for signifi
Autor:
Stefan Goemaere, Kim Brixen, Adolfo Diez-Perez, Dieter Felsenberg, Steven Boonen, C. Cormier, Adam Balogh, Maria Luisa Brandi, Jean-Yves Reginster, René Rizzoli, Pierre D. Delmas, Pierre J. Meunier, Tim D. Spector
Publikováno v:
Arthritis and Rheumatism, Vol. 58, No 6 (2008) pp. 1687-95
Reginster, J-Y, Felsenberg, D, Boonen, S, Diez-Perez, A, Rizzoli, R, Brandi, M-L, Spector, T D, Brixen, K, Goemaere, S, Cormier, C, Balogh, A, Delmas, P D & Meunier, P J 2008, ' Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis : Results of a five-year, randomized, placebo-controlled trial ', Arthritis & Rheumatism, vol. 58, no. 6, pp. 1687-1695 . https://doi.org/10.1002/art.23461
Reginster, J-Y, Felsenberg, D, Boonen, S, Diez-Perez, A, Rizzoli, R, Brandi, M-L, Spector, T D, Brixen, K, Goemaere, S, Cormier, C, Balogh, A, Delmas, P D & Meunier, P J 2008, ' Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis : Results of a five-year, randomized, placebo-controlled trial ', Arthritis & Rheumatism, vol. 58, no. 6, pp. 1687-1695 . https://doi.org/10.1002/art.23461
Udgivelsesdato: 2008-Jun OBJECTIVE: This study was undertaken to assess the effect of strontium ranelate on nonvertebral and vertebral fractures in postmenopausal women with osteoporosis in a 5-year, double-blind, placebo-controlled trial. METHODS: A